Goodrx Holdings Inc
$ 2.75
0.36%
04 Dec - close price
- Market Cap 955,487,000 USD
- Current Price $ 2.75
- High / Low $ 2.78 / 2.70
- Stock P/E 34.38
- Book Value 1.76
- EPS 0.08
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.05 %
- 52 Week High 5.81
- 52 Week Low 2.61
About
GoodRx Holdings, Inc. is a leading digital healthcare platform in the United States that revolutionizes consumer access to prescription medications by providing transparent pricing and savings options. With its headquarters in Santa Monica, California, GoodRx has established strategic partnerships with pharmacies and healthcare providers to enhance affordability and improve health outcomes for millions of users. As the healthcare sector undergoes significant digital transformation, GoodRx is well-positioned to expand its market presence and address the changing needs of consumers, driving value in a critical industry.
Analyst Target Price
$5.09
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-09 | 2023-08-09 | 2023-05-10 | 2023-02-28 |
| Reported EPS | 0.08 | 0.09 | 0.09 | 0.09 | 0.08 | 0.08 | 0.08 | 0.08 | 0.06 | 0.07 | 0.07 | 0.07 |
| Estimated EPS | 0.0902 | 0.1 | 0.0957 | 0.0959 | 0.09 | 0.09 | 0.08 | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 |
| Surprise | -0.0102 | -0.01 | -0.0057 | -0.0059 | -0.01 | -0.01 | 0 | 0.01 | 0 | 0.01 | 0.01 | 0.02 |
| Surprise Percentage | -11.3082% | -10% | -5.9561% | -6.1522% | -11.1111% | -11.1111% | 0% | 14.2857% | 0% | 16.6667% | 16.6667% | 40% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GDRX
2025-11-02 11:00:38
GoodRx Holdings, Inc. announced its financial results for Q4 and the full year 2024, reporting revenue of $198.6 million for Q4 and $792.3 million for the full year, a 6% increase from 2023. The company achieved a net income of $16.4 million for the full year, a significant improvement from a net loss in the previous year, and provided revenue guidance for Q1 and full year 2025. Strategic initiatives focused on capital allocation, debt reduction, and growth contributed to its performance.
2025-11-02 11:00:38
This page provides live quotes and charts for GoodRx Holdings Inc. (GDRX) stock, showing its current price, daily change, and price history. It also includes an analyst ratings section, which currently indicates no available data, and states that earnings information for GoodRx Holdings Inc. is not available.
2025-10-15 13:02:06
GoodRx has launched a new subscription service for men's hair loss treatment, offering affordable and convenient access to clinically proven medications like oral finasteride and minoxidil. Starting at $16/month, the service includes virtual consultations, prescriptions, and discreet home delivery, aiming to simplify access for the many men who experience hair loss. This initiative provides a transparent alternative to complex multi-product kits often seen in the market.
2025-10-15 13:00:00
GoodRx (NASDAQ:GDRX) has launched a new subscription service for men's hair loss treatment, aiming to simplify access to affordable, clinically proven solutions. The service includes a virtual consultation, prescription medication, and discreet home delivery, starting as low as $16 per month. This initiative is designed to offer a straightforward alternative to complex and expensive multi-step kits often provided by competitors, providing transparent pricing and convenient delivery.
2025-08-25 00:00:00
Shares for Santa Monica-based GoodRx climbed by 37% after announcing a deal with Novo Nordisk to offer significantly discounted Wegovy and Ozempic to self-paying customers for $499 for a month’s supply. This deal, a departure from their usual manufacturer partnerships, is a major marketing coup for GoodRx and CEO Wendy Barnes, aiming to address high demand and accessibility issues for GLP-1 medications. The stock saw a significant initial surge, though it tempered in subsequent trading sessions, reflecting its short-term impact on the company's long-term stock performance.
2025-08-18 13:00:21
GoodRx announced a deal to sell Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, for a cash price of $499 per month, causing its stock to soar by over 30%. This partnership aims to increase access to these in-demand medications and comes as Novo Nordisk faces market share challenges from Eli Lilly's Zepbound. GoodRx emphasizes selling only FDA-approved versions, distinguishing its strategy from platforms that previously offered compounded alternatives.
